Recent study findings indicate that Escherichia
coli antimicrobial-resistance to ciprofloxacin for urinary tract infections
increased more than five-fold between 2000 and 2010.
Our study reveals that ciprofloxacin and
trimethoprim-sulfamethoxazole are no longer safe for outpatient urinary tract
infections, Jose Bordon, MD, PhD, an infectious disease specialist
at Providence Hospital, said in a press release.
Bordon and colleagues from George Washington University
and Providence Hospital in Washington, D.C. studied antimicrobial
susceptibility data for urinary E. coli isolates obtained from
outpatients between 2000 and 2010. The data were obtained from the Surveillance
Network Database, which includes data from 200 institutions in the United
States. The study included more than 12 million urinary E. coli
The greatest increase in resistance among the isolates
was observed for ciprofloxacin, which showed a resistance rate of 3% in 2000
and a resistance rate of 17.1% in 2010. Resistance to
trimethoprim-sulfamethoxazole increased from 17.9% in 2000 to 24.2% in 2010.
Nitrofurantoin, amoxicillin-clavulanate and ceftriaxone only indicated small
changes to resistance.
Our study indicates that safer antimicrobials for
outpatient urinary tract infections are nitrofurantoin in patients without
kidney insufficiency and amoxicillin/clavulanate and third generation
cephalosporins for all others, Bordon said in the press release.
- Sanchez GV. Antimicrob Agents Chemother. 2012;56:2181-2183
- The authors report no relevant